Coumadin

Coumadin is used for treating and preventing harmful clots that may occur in the veins (venous thrombosis), in the lungs (pulmonary embolism), with a type of abnormal heartbeat (atrial fibrillation), or following a heart valve replacement.

Product dosage: 1mg
Package (num)	Per pill	Price	Buy
180	$0.34	$61.00 (0%)	🛒 Add to cart
270	$0.30	$91.50 $81.00 (11%)	🛒 Add to cart
360	$0.29 Best per pill	$122.00 $104.00 (15%)	🛒 Add to cart

Product dosage: 2mg
Package (num)	Per pill	Price	Buy
90	$0.44	$40.00 (0%)	🛒 Add to cart
120	$0.39	$53.33 $47.00 (12%)	🛒 Add to cart
180	$0.34	$80.00 $61.00 (24%)	🛒 Add to cart
270	$0.30	$120.00 $81.00 (32%)	🛒 Add to cart
360	$0.29 Best per pill	$160.00 $104.00 (35%)	🛒 Add to cart

Product dosage: 5mg
Package (num)	Per pill	Price	Buy
30	$1.33	$40.00 (0%)	🛒 Add to cart
60	$0.77	$80.00 $46.00 (42%)	🛒 Add to cart
90	$0.63	$120.00 $57.00 (52%)	🛒 Add to cart
120	$0.56	$160.00 $67.00 (58%)	🛒 Add to cart
180	$0.49	$240.00 $89.00 (63%)	🛒 Add to cart
270	$0.45	$360.00 $121.00 (66%)	🛒 Add to cart
360	$0.42 Best per pill	$480.00 $153.00 (68%)	🛒 Add to cart
Synonyms Aldocumar Anasmol Arefarin Choice Circuvit Coumadine Coumafene Cumar Farevan Fargem Farin Hemeran Jantoven Kovar Lawarin Marevan Marfarin Marivarin Martefarin Orfarin Panwarfin Simarc Uniwarfin Warafin Waran Warfant Warfarex Warfarina Warfarine Warfarinum Warfilone Warfin Warin Warlin

Coumadin (warfarin sodium) is a cornerstone oral anticoagulant therapy, meticulously engineered to reduce the formation of harmful blood clots. It functions as a vitamin K antagonist, systematically inhibiting the synthesis of vitamin K-dependent clotting factors (II, VII, IX, and X) in the liver, thereby prolonging clotting time. This mechanism provides a predictable and titratable anticoagulant effect, making it a critical agent for long-term thromboembolic risk management. Its use requires careful medical supervision through regular INR (International Normalized Ratio) monitoring to ensure therapeutic efficacy while minimizing bleeding risks.

Features

• Active Ingredient: Warfarin Sodium.
• Pharmacological Class: Vitamin K Antagonist (VKA) oral anticoagulant.
• Available Formulations: Scored tablets in multiple strengths (e.g., 1 mg, 2 mg, 2.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, 7.5 mg, 10 mg), often color-coded for easy identification.
• Mechanism of Action: Inhibits the vitamin K epoxide reductase complex (VKORC1), suppressing the hepatic synthesis of biologically active forms of the vitamin K-dependent clotting factors.
• Onset of Action: Therapeutic anticoagulant effect is typically delayed for 36-72 hours as existing clotting factors clear from the bloodstream.
• Duration of Action: 2-5 days; long biological half-life necessitates careful management.
• Monitoring Parameter: Dosing is guided by frequent prothrombin time (PT) testing, reported as the International Normalized Ratio (INR).

Benefits

• Proven Reduction in Stroke and Systemic Embolism: Significantly decreases the risk of life-threatening thromboembolic events in patients with conditions like atrial fibrillation and mechanical heart valves.
• Effective Treatment and Prevention of Venous Thromboembolism (VTE): Established efficacy in managing deep vein thrombosis (DVT) and pulmonary embolism (PE), both for acute treatment and secondary prevention.
• Oral Administration Convenience: Provides a practical option for long-term, outpatient anticoagulation management compared to injectable alternatives.
• Titratable and Reversible Effect: The anticoagulant effect can be precisely adjusted via dose titration and, if necessary, reversed using vitamin K, fresh frozen plasma, or prothrombin complex concentrates.
• Extensive Clinical Legacy: Decades of real-world use and clinical research provide a deep, well-understood safety and efficacy profile for healthcare providers.
• Cost-Effective Therapy: Often available as a generic (warfarin), making it a financially accessible long-term treatment option.

Common use

Coumadin is indicated for the prophylaxis and/or treatment of:

• Thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement.
• Venous thrombosis and its extension, and pulmonary embolism.
• Post-myocardial infarction to reduce the risk of death, recurrent infarction, and thromboembolic events such as stroke or systemic embolization (use in this context has become less common with the advent of newer antiplatelet regimens).
• Adjunctive therapy in patients undergoing cardioversion of atrial fibrillation to prevent thromboembolic events.

Dosage and direction

Administration is highly individualized based on the patient’s INR response. The following is general guidance; a healthcare provider must determine the exact regimen.

• Initial Dosing: For most adults, a starting dose of 2-5 mg once daily is typical for the first 1-2 days. Dosing algorithms may consider factors like age, weight, genetics (e.g., CYP2C9 and VKORC1 genotype), concomitant medications, and comorbidities.
• Maintenance Dosing: The daily maintenance dose is determined by periodic INR measurements. The goal is to find the smallest dose that maintains the INR within the target therapeutic range (e.g., INR 2.0-3.0 for most indications, or 2.5-3.5 for mechanical mitral valves).
• Frequency: Taken orally once daily, preferably at the same time each day.
• Administration: Can be taken with or without food. Consistency in diet (particularly vitamin K intake) is crucial.
• Monitoring: INR must be checked frequently during initiation and dose adjustment (e.g., every 1-3 days), and at longer intervals (e.g., every 2-4 weeks) once stable.

Precautions

• Bleeding Risk: Coumadin increases the risk of serious and potentially fatal bleeding. Patients must be instructed to recognize signs of bleeding (unusual bruising, pink/red urine, black/tarry stools, coughing blood, unusual headache) and seek immediate medical attention.
• Regular INR Monitoring is Mandatory: Never adjust the dose without an INR test. The frequency of monitoring should not be reduced based on a stable dose alone.
• Dietary Consistency: Patients should maintain a consistent intake of vitamin K-rich foods (e.g., leafy green vegetables, broccoli, Brussels sprouts). They should not avoid these foods but rather keep their intake steady from week to week.
• Alcohol: Consumption should be limited as it can affect INR.
• Pregnancy: Coumadin is contraindicated in pregnancy (especially the first trimester and last few weeks of pregnancy) due to high risk of birth defects and fetal hemorrhage. Women of childbearing potential must use effective contraception.
• Illness: Conditions that affect nutrition, liver function, or gut flora (e.g., diarrhea, vomiting, fever, infection) can alter INR response. Healthcare providers should be notified of any significant illness.

Contraindications

• Hemorrhagic tendencies or blood dyscrasias.
• Recent or planned surgery of the eye, central nervous system, or traumatic surgery resulting in large open surfaces.
• Active ulceration or overt bleeding of the gastrointestinal, genitourinary, or respiratory tracts.
• Cerebral aneurysm, dissecting aorta, pericarditis, pericardial effusion.
• Threatened abortion, eclampsia, preeclampsia.
• Unsupervised patients with senility, alcoholism, psychosis, or lack of compliance.
• Spinal puncture or other diagnostic or therapeutic procedures with potential for uncontrollable bleeding.
• Hypersensitivity to warfarin or any component of the product.
• Major regional or lumbar block anesthesia.
• Malignant hypertension.

Possible side effect

• Common: Bleeding of varying severity (ecchymosis, epistaxis, gingival bleeding, menorrhagia).
• Less Common: Gastrointestinal disturbances (nausea, vomiting, diarrhea, abdominal pain), hair loss, rash, dermatitis, cholestatic hepatitis.
• Serious (Require Immediate Medical Attention): Severe hemorrhage (e.g., intracranial, retroperitoneal), gangrene of skin and other tissues (often associated with protein C deficiency), purple toe syndrome, necrosis of the skin, tracheobronchial calcification, systemic atheroemboli and cholesterol microemboli.
• Other: A unique adverse effect is the rare occurrence of acute, painful, red-tinged plaques on the extremities and torso, which can progress to necrosis.

Drug interaction

Coumadin has a vast and potentially dangerous number of drug interactions. The list below is not exhaustive. Always consult a comprehensive reference or pharmacist.

• Drugs that Potentiate Anticoagulant Effect (Increase INR): Acetaminophen (chronic use), Amiodarone, Antiplatelets (e.g., aspirin, clopidogrel), SSRIs/SNRIs, Many antibiotics (e.g., sulfamethoxazole/trimethoprim, fluconazole, metronidazole), Omeprazole, Simvastatin, Thyroid hormones, Cimetidine.
• Drugs that Inhibit Anticoagulant Effect (Decrease INR): Barbiturates, Carbamazepine, Cholestyramine, Nafcillin, Rifampin, Vitamin K, St. John’s Wort.
• Drugs that Increase Bleeding Risk (Additive Effect): NSAIDs (e.g., ibuprofen, naproxen), other anticoagulants (e.g., heparin, DOACs), antiplatelets, SSRIs.

Missed dose

• If remembered on the same day, the dose should be taken as soon as possible.
• If remembered the next day, the missed dose should be skipped. The patient should never take a double dose to make up for a missed dose.
• The healthcare provider should be informed of the missed dose at the next visit or contact, as it may affect the timing of the next INR test.

Overdose

Overdose manifests as excessive anticoagulation and/or bleeding.

• Signs/Symptoms: Blood in urine or stool, excessive bruising, prolonged bleeding from cuts, heavy menstrual flow, headache, dizziness, weakness.
• Action: Seek emergency medical attention immediately. Treatment is based on the degree of INR elevation, the presence of bleeding, and clinical circumstances. Options include withholding Coumadin, administering oral or intravenous vitamin K, or in cases of serious bleeding, transfusion of fresh frozen plasma or prothrombin complex concentrate.

Storage

• Store at room temperature (20°-25°C or 68°-77°F) in a tight, light-resistant container.
• Keep out of reach of children and pets.
• Do not use after the expiration date printed on the bottle.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read here. The author and publisher are not responsible for any errors or omissions or for any consequences from application of the information in this document.

Reviews

• “As a cardiologist with 30 years of experience, warfarin remains a vital tool. Its reversibility and our deep familiarity with its management profile make it indispensable for certain high-risk patients, despite the need for diligent monitoring.” – Dr. A. Reynolds, MD, Cardiology
• “Managing my INR is a commitment, but it gives me peace of mind. After my pulmonary embolism, my care team has worked with me to find a stable dose. The key is consistency and communication.” – Patient, Long-term user (7 years)
• “From a pharmacy perspective, Coumadin interactions are among the most critical we screen for. It demands vigilance with every new prescription a patient receives. Patient education on signs of bleeding is paramount.” – J. Chen, PharmD
• “The transition from heparin to warfarin post-DVT was straightforward. The weekly blood tests were a minor inconvenience for the significant protection it provides against another clot.” – Patient, 1-year user